Dive Brief:
- The FDA wants to expand warnings on testosterone products to include a general warning about vein blood clots, Reuters reports.
- The agency noted the products already include a warning about blood clots for a condition that can occur during testosterone treatment, but the new proposal would be wider in scope.
- The warning is not related to the agency's ongoing investigation of the risk of stroke and heart attack in men taking the drugs, the FDA said.
Dive Insight:
The new proposal adds to the list of warnings that have come up over the use of prescription testosterone. Drugwatch.com reports prescription testosterone gels were a $2 billion business in 2012, with experts believing sales will double by 2017.